IKK

IκB kinase;I kappa B kinase



IKK (IκB kinase) is an enzyme complex that is involved in propagating the cellular response to inflammation. An IκB kinase is an enzyme that catalyzes the chemical reaction: ATP + IκB protein ADP + IκB phosphoprotein. The IκB kinase enzyme complex is part of the upstream NF-κB signal transduction cascade. The IκBα (inhibitor of kappa B) protein inactivates the NF-κB transcription factor by masking the nuclear localization signals of NF-κB proteins and keeping them sequestered in an inactive state in the cytoplasm. IKK specifically, phosphorylates the inhibitory IκBα protein. This phosphorylation results in the dissociation of IκBα from NF-κB. NF-κB, which is free migrates into the nucleus and activates the expression of at least 150 genes; some of which are anti-apoptotic. IKK belongs to the family of transferases, specifically those transferring a phosphate group to the sidechain oxygen atom of serine or threonine residues in proteins.

IKK Inhibitors & Modulators

ACHP Hydrochloride

(IKK-2 Inhibitor VIII)

Cat. No.: HY-13060

Bioactivity: ACHP Hydrochloride is a highly potent and selective **IKK-β** inhibitor with an **IC_{50}** of 8.5 nM.

Purity: 98.03%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg, 100 mg



Amlexanox

(AA673; Amoxanox; CHX3673)

Cat. No.: HY-B0713

Bioactivity: AmLexanox is a specific inhibitor of **IKKε** and **TBK1**, and inhibits the IKKε and TBK1 activity determined by MBP phosphorylation with an **IC_{50}** of approximately 1-2 μM.

Purity: 99.32%
Clinical Data: Launched
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg, 100 mg



AZD3264

Cat. No.: HY-19362

Bioactivity: AZD3264 is a selective IkB-kinase **IKK2** inhibitor.

Purity: 98.77%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg, 100 mg



Bay 65-1942 free base

Cat. No.: HY-50949

Bioactivity: Bay 65-1942 free base is an ATP-competitive and selective **IKKβ** inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



Bay 65-1942 hydrochloride

Cat. No.: HY-50948

Bioactivity: Bay 65-1942 hydrochloride is an ATP-competitive and selective **IKKβ** inhibitor.

Purity: 99.05%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg



Bay 65-1942 R form

Cat. No.: HY-50949A

Bioactivity: Bay 65-1942 R form is the less active R-form of Bay 65-1942. Bay 65-1942 is an ATP-competitive and selective IKKβ inhibitor.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg



BI605906

Cat. No.: HY-13019

Bioactivity: BI605906 is a novel **IKKβ** inhibitor with an **IC_{50}** value of 380 nM when assayed at 0.1 mM ATP.

Purity: 99.68%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg



BMS-066

Cat. No.: HY-18710

Bioactivity: BMS-066 is an **IKKβ/Tyk2** pseudokinase inhibitor, with **IC_{50}s** of 9 nM and 72 nM, respectively.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



BMS-345541

(BMS-345541 hydrochloride)

Cat. No.: HY-10518

Bioactivity: BMS-345541 is a selective inhibitor of the catalytic subunits of **IKK** (**IKK-2 IC_{50}**=0.3 μM, **IKK-1 IC_{50}**=4 μM). BMS-345541 binds at
an allosteric site of IKK.

Purity: 99.77%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 50 mg



BMS-345541 free base

Cat. No.: HY-10519

Bioactivity: BMS-345541 free base is a selective inhibitor of the catalytic subunits of **IKK** (**IKK-2 IC_{50}**=0.3 μM, **IKK-1 IC_{50}**=4 μM).
BMS-345541
binds at an allosteric site of IKK.

Purity: 99.17%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 50 mg



Tel: 4008203792 Fax: 021-53700325 Email: sales@MedChemExpress.cn

Ertiprotafib

(PTP 112)

Cat. No.: HY-19383

Bioactivity: Ertiprotafib is an inhibitor of **PTP1B, IkB kinase β (IKK-β)**, and a dual **PPARα and PPARβ** agonist, with an IC_{50} of 1.6 μM for PTP1B, 400 nM for IKK-β, an EC_{50} of ~1 μM for PPARα/PPARβ.

Purity: >98%
Clinical Data: No Development Reported
Size: 250 mg, 500 mg



GSK319347A

(IKK-3 Inhibitor)

Cat. No.: HY-14682

Bioactivity: IKK-3 Inhibitor is a dual inhibitor of **TBK1** and **IKKε** with IC_{50}s of 93 nM and 469 nM, respectively. IKK-3 Inhibitor also inhibits **IKK2** with an IC_{50} of 790 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg



IKK 16

Cat. No.: HY-13687

Bioactivity: IKK 16 is a selective IκB kinase (**IKK**) inhibitor for **IKK2**, **IKK complex** and **IKK1** with IC_{50}s of 40 nM, 70 nM and 200 nM, respectively. IKK16 also inhibits leucine-rich repeat kinase-2 (**LRRK2**) with an IC_{50} of 50 nM.

Purity: 99.78%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 10 mg, 50 mg



IKK-IN-1

Cat. No.: HY-13873

Bioactivity: IKK-IN-1 is an inhibitor of **IKK** extracted from patent WO2002024679A1, compound example 18-13.

Purity: 95.04%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg



IMD-0354

(IKK2 Inhibitor V)

Cat. No.: HY-10172

Bioactivity: IMD-0354 is a selective **IKKβ** inhibitor which inhibits NF-κB activity. IMD0354 inhibits TNF-α induced NF-κB transcription activity with an IC_{50} of 1.2±0.3 uM.

Purity: 99.46%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



IMD-0560

Cat. No.: HY-105661

Bioactivity: IMD-0560 is a novel **IκB kinase β** inhibitor.

Purity: 98.68%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg



LY2409881

Cat. No.: HY-B0788

Bioactivity: LY2409881 is a selective IκB kinase β (**IKK2**) inhibitor with an IC_{50} of 30 nM.

Purity: 98.89%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



LY2409881 trihydrochloride

Cat. No.: HY-B0788A

Bioactivity: LY2409881 trihydrochloride is a selective IκB kinase β (**IKK2**) inhibitor with an IC_{50} of 30 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 2 mg, 5 mg, 10 mg, 50 mg, 100 mg



MLN120B

(ML120B)

Cat. No.: HY-15473

Bioactivity: MLN120B is a specific, ATP competitive **IKKβ** inhibitor with an IC_{50} of 60 nM.

Purity: 99.03%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg



MRT67307

Cat. No.: HY-13018

Bioactivity: MRT67307 is a dual inhibitor of the **IKKε** and **TBK-1** with IC_{50}s of 160 and 19 nM, respectively. MRT67307 also inhibits ULK1 and ULK2 with IC_{50}s of 45 and 38 nM, respectively.

Purity: 99.00%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO, 5 mg, 10 mg, 50 mg, 100 mg



PS-1145

Cat. No.: HY-18008

Bioactivity: PS-1145 is an IκB kinase (**IKK**) inhibitor with an **IC_{50}** of 88 nM.

Purity: 99.85%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 25 mg, 50 mg, 100 mg



Resveratrol

(SRT 501; trans-Resveratrol)

Cat. No.: HY-16561

Bioactivity: Resveratrol (SRT 501), a natural polyphenol that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. It has a wide spectrum of targets including **mTOR**, **JAK**, **β-amyloid**.

Purity: 98.90%
Clinical Data: Phase 4
Size: 10mM x 1mL in DMSO,
200 mg, 500 mg



SC-514

(GK 01140)

Cat. No.: HY-13802

Bioactivity: SC-514 is a selective **IKK-2** inhibitor (**IC_{50}**=11.2±4.7 μM), which does not inhibit other IKK isoforms or other serine-threonine and tyrosine kinases.

Purity: 99.99%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
10 mg, 50 mg



TBK1/IKKε-IN-1

Cat. No.: HY-U00457

Bioactivity: TBK1/IKKε-IN-1 is a dual **TBK1** and **IKKε** inhibitor extracted from patent US20160376283 A1, Compound 274 in Example 60, has **IC_{50}**s of <100 nM.

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg



TBK1/IKKε-IN-2

Cat. No.: HY-12453

Bioactivity: TBK1/IKKε-IN-2 is a dual **TBK1** and **IKKε** inhibitor.

Purity: 98.50%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
2 mg, 5 mg, 10 mg, 50 mg, 100 mg



TPCA-1

Cat. No.: HY-10074

Bioactivity: TPCA-1 is a potent and selective inhibitor of **IKK-2** with **IC_{50}** of 17.9 nM.

Purity: 99.54%
Clinical Data: No Development Reported
Size: 10mM x 1mL in DMSO,
5 mg, 10 mg, 100 mg